Latest news

As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.

The GeoMx Whole Transcriptome Atlas (WTA) empowers to explore biology accross a tissue. The human whole transcriptome (over 18,000 protein-coding human genes) is measured in each region of interest to uncover biological changes at specific locations of the tissue. 

• Whole transcriptome coverage with probes specific to protein coding mRNA sequences


• Compatible with common sample types such as formalin-fixed paraffin embedded (FFPE) or fresh frozen (FF) tissue and across all human tissues types


• Superior sensitivity to detect 1000s of unique human genes in <50 μm regions


• Robust performance across sample types including FFPE with high concordance with RNA-seq and RNAscope™


• Map single cell RNA-seq populations to their tissue location

 



The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.

The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.

 

Learn about out Digitial Spatial Profiling (DSP) services

The Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of the tumor biology, tumor microenvironment, and the immune response. It covers the RNA expression of over 1,800 genes simultaneously with spatial resolution in any region of interest from a single tissue section.

The CTA assay is compatible with RNAscope® and antibody visualization markers. It can also be supplemented with up to 60 additional targets of interest.

Learn about out spatial transcriptomics services

Comprehensively Annotated Pathways in the CTA

Adaptive Immunity		Cell Function		Signaling Pathways
T cells B cells		Apoptosis		AMPK Signaling
TCR & BCR Signaling		Autophagy		Androgen Signaling
Cancer Antigens		Cell Adhesion & Motility		EGFR Signaling
MHC Class I & II Antigen Presentation		Cell Cycle		ERBB2 Signaling
T-cell Checkpoints		Cilium Assembly		Estrogen Signaling
TH1, TH2, TH9, Th17, and Treg Differentiation		Differentiation		FGFR Signaling
		DNA Damage Repair		FoxO Signaling
Innate Immunity		EMT		GPCR Signaling
Complement System		Endocytosis		Hedgehog Signaling
Dendritic Cells		Epigenetic Modification		HIF1 Signaling
DNA & RNA Sensing		Immortality & Stemness		Insulin Signaling
Glycan Sensing		Ion Transport		JAK-STAT Signaling
Host Defense Peptides		Lysosome		MAPK Signaling
Inflammasomes		Oxidative Stress		MET Signaling
Myeloid Inflammation		Phagocytosis		mTOR Signaling
Neutrophil Degranulation		Proteotoxic Stress		Myc
NK Activity		RNA Processing		NO Signaling
NLR Signaling		Senescence		Notch Signaling
RAGE Signaling				p53 Signaling
TLR Signaling		Metabolism		PDGF Signaling
		Amino Acid Synthesis & Transport		PI3K-Akt Signaling
Immune Response		Arginine & Glutamine Metabolism		PPAR Signaling
Chemokine Signaling		Fatty Acid Oxidation & Synthesis		Purinergic Signaling
Cytotoxicity		Glycolysis & Glucose Transport		Retinoic Acid Signaling
IL-1, IL-2, IL-6 & IL-17 Signaling		Glycosylation		TGF-beta Signaling
Immune Exhaustion		IDH1/2		VEGF Signaling
Interferon Response Genes		Lipid Metabolism		Wnt Signaling
Lymphocyte Regulation & Trafficking		Mitochondrial Metabolism / TCA
NF-kB Signaling		Nucleotide Synthesis		Physiology & Disease
Other Interleukin Signaling		Pentose Phosphate		Angiotensin System
Prostaglandin Inflammation		Tryptophan & Kynurenine Metabolism		Circadian Clock
TNF Signaling		Vitamin & Cofactor Metabolism		Drug Resistance
Type I, II, & III Interferon Signaling				Glioma
				Leukemia
				Matrix Remodeling and Metastasis
				Melanoma
				Neuroendocrine Function
				Prostate Cancer

Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.

Drawing on our expertise in IHC and IHF assays, we have developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets.